Figs Inc. (FIGS)
NYSE NYSE Primary 
Countdown to Figs (FIGS) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
Beyond analysts' top -and-bottom-line estimates for Figs (FIGS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.
Scrubs maker Figs rebuffs Story3 Capital's take-private offer
Figs said on Thursday it has rebuffed private equity firm Story3 Capital Partners' offer to acquire the scrubs maker.
Figs stock price sits in a range: will it have a breakout in 2025?
Figs stock has lost momentum and remained in a consolidation phase in almost two years. It remained inside the support and resistance levels at $4.42 and $6.97 in this period, missing the strong stock surge in the United States.
FIGS: Opportunistic Bid Grossly Undervalues A Recession Proof Business
An opportunistic offer by a PE fund during a 'retail lull' grossly undervalues FIGS, thus providing a chance for value and arbitrage investors to profit from the situation. Founded by Heather Hasson and Trina Spear, the stock has dropped from over $35 to $6.07 since its 2021 IPO and subsequent takeover offer. Story3 Capital's $6 per share offer to take the company private undervalues the business, which has strong free cash flow and no debt.
Is Figs a Buy After $1 Billion Buyout Rumors?
Shares of Figs (FIGS -3.85%) jumped this week after the company reportedly received a buyout offer for around $1 billion. In this video, Travis Hoium shows why private equity buyers may be interested and what the stock could do now.
Medical-Apparel Maker Figs Gets Takeover Bid From Private-Equity Firm
The Story3 proposal values the company at more than $1 billion.
Medical-Apparel Maker Figs Gets Takeover Bid From Private-Equity Firm
The Story3 proposal values the company at more than $1 billion.
FIGS Back To Q1 Prices, But The Name Is Still A Hold
Figs reported disappointing 3Q24 results with a 2% revenue decline and a 13 percentage point drop in adjusted EBITDA margins, leading to a 30% stock price drop. The company's high SG&A expenses and lack of growth make it difficult to compete against lower-priced alternatives, justifying my Hold rating. Questionable $25 million investment in a pre-product healthcare education app raises concerns about capital allocation and potential conflicts of interest.
FIGS, Inc. (FIGS) Q3 2024 Earnings Call Transcript
FIGS, Inc. (NYSE:FIGS ) Q3 2024 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Tom Shaw - Senior Vice President, Investor Relations Trina Spear - Co-Founder & Chief Executive Officer Sarah Oughtred - Chief Financial Officer Conference Call Participants Dana Telsey - Telsey Group Josh Reiss - Raymond James Bob Drbul - Guggenheim Brooke Roach - Goldman Sachs Brian Nagel - Oppenheimer Lorraine Hutchinson - Bank of America Matt Koranda - ROTH Capital Nathan Feather - Morgan Stanley John Kernan - TD Cowen Ashley Owens - KeyBanc Capital Markets Operator Thank you for standing by, and good afternoon. Thank you for attending today's FIGS' Third Quarter Fiscal 2024 Earnings Conference Call.
Figs (FIGS) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Figs (FIGS) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
FIGS, Inc.: Growth Potentially Inflecting Upwards
I rate FIGS, Inc. stock as a buy, expecting growth to inflect upwards with orders per buyer potentially more than doubling. FIGS has enhanced top-of-funnel awareness, product innovation, and distribution capacity, driving customer acquisition beyond its core scrub customer base. Margin pressures are temporary; scaling non-scrub products and the high-margin TEAMS business should flip this headwind into a tailwind.
FIGS Q2 2024 Shows Growth At The Expense Of Margins. The Stock Is Still Overpriced
FIGS' Q2 2024 results showed moderate revenue growth but at the expense of lower margins due to increased spending on products and marketing. The company's lack of cost management and high gross margins make it vulnerable to competition, justifying my Hold rating. Despite some improvement in guidance, the valuation remains unattractive with the stock trading at a high P/E ratio even under optimistic scenarios.
